You may recall our discussion of a new treatment for Vitreomacular Adhesion (VMA) called Jetrea. Thrombogenics, the makers of Jetrea, now offers an option other than surgery for VMA. Rather than undergoing surgery, a patient can now opt for in-office intravitreal injection. This procedure involves an intravitreal injection similar to how we treat wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO) but with a different medication. According to research this procedure has an approximate 40% success rate.

This medication comes to us frozen and must be kept frozen until the time of treatment. We were provided with a freeze that we use exclusively for Jetrea. Once ordered, this medication arrives to us the very next day in a large insulated box.

Within this insulated box is a Styrofoam ice-chest filled with dry ice.

Embedded within the dry ice is a sealed plastic bag with the boxes of medication.

We carefully open the container and place the Jetrea into the freezer until it is thawed and injected.

As I mentioned, our results have been very positive. Below you can see a Before and After OCT scan of the same patient.

Before Jetrea- Note the vitreomacular adhesion and macular hole:

After Jetrea s/p 1 week- Note the resolution of VMA, closure of macular hole, and small amount of subfoveal subretinal fluid:

After Jetrea s/p 1 month- Note that the subretinal fluid is almost resolved:

I anticipate more improvement at this patient’s next visit in one month. For more information, please call the office at 808.676.4772.